Latest News & Features

Reset all filters
Article Type
Channels & Sectors

Refine Search
Hongene Biotech challenged ChemGenes’ patent after litigation withdrawn | Judges said all challenged claims were unpatentable.   25 July 2024
AI has the potential to revolutionise patent examination but uneven adoption of the technology could undermine fairness in the system, says Matthew Veale of Patsnap.   25 July 2024
The appointee represents a diverse range of tech clients, including in medtech and life sciences and will now lead the firm’s California offices.   25 July 2024
Scientist and patent attorney joins boutique IP firm in Philadelphia | Former in-house counsel brings expertise representing variety of life sciences clients.   25 July 2024
House of Representatives introduces bill to drive down cost of prescription drugs | Places “reasonable limit” on the number of patents a manufacturer can contest to prevent patent ‘thickets’ | Companion bill passed Senate earlier this month.   23 July 2024
Paris Central Division issues its first revocation judgment in dispute brought by Meril subsidiaries in Italy, Germany and India | Decision means infringement action by Edwards can resume at Munich Local Division | Damages worth €8m ($8.7m) | Gide, Marks & Clerk, Potter Clarkson among representatives.   23 July 2024
Commission upholds judge’s finding that Gator Bio did not infringe lab equipment patent | Sartorius sought to assert remaining patent-in-suit covering bio-layer interferometers.   18 July 2024
First patent filed using the new digital One IPO service | AI-powered internal tool to speed up the application process | Set for public launch in 2025 with a promise to “revolutionise” patent management.   18 July 2024
Guidance says use of AI in inventing does not affect how patent claims are assessed for eligibility | Emphasis placed on evaluating inventions themselves rather than the method of creation | Updates include new examples to assist examiners in evaluating AI-related patent claims.   18 July 2024
Big Pharma
New bill anticipated to depart from previous government’s light-touch approach to AI regulation | Attorneys fear “onerous or conflicting” requirements on pharma and biotech companies.   16 July 2024